Robert Michael Dudley - 20 Jun 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol: RNAZ
Transactions as of: 20 Jun 2023
Transactions value $: $48,665
Form type: 4
Filing time: 22 Jun 2023, 18:23:24 UTC
Previous filing: 14 Jun 2023
Next filing: 02 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNAZ	Common Stock	Purchase	$16.8K	+6.61K	+10.38%	$2.55	70.3K	20 Jun 2023	Direct	F1
transaction	RNAZ	Common Stock	Purchase	$31.8K	+12K	+17.08%	$2.65	82.3K	21 Jun 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
F2	Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

Content

Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.